News Column

Lilly Reports Second-Quarter 2014 Results

August 4, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- Second-quarter 2014 revenue declined 17 percent driven by the impact of

U.S. patent expirations for Cymbalta and Evista, partially offset by

volume growth in several other products (see also Eli Lilly and Company).

-- Expense management initiatives resulted in 11 percent OPEX reduction,

partially offsetting revenue declines.

-- Second-quarter 2014 earnings per share were $0.68 on both a reported and

Keywords for this news article include: Eli Lilly and Company.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Pharma Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters